Ruowen Yuan

Dr. Ruowen Yuan


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XZXiaowei Zhang
Xiaowei Zhang
YLYongnan Li
Yongnan Li
YXYixin Xie
Yixin Xie
JBJia-Le Bu
Jia-Le Bu
RYRuowen Yuan
Ruowen Yuan
XZXiaowei Zhang
Xiaowei Zhang
With increasing research, the sirtuin (SIRT) protein family has become increasingly understood. Studies have demonstrated that SIRTs can aid in metabolism and affect various physiological processes, such as atherosclerosis, heart failure (HF), hypertension, type 2 diabetes, and other related disorders. Although the pathogenesis of HF with preserved ejection fraction (HFpEF) has not yet been clarified, SIRTs have a role in its development. Therefore, SIRTs may offer a fresh approach to the diagnosis, treatment, and prevention of HFpEF as a novel therapeutic intervention target.

17 March 2023 in Medicina
Verified
Journal Article
Open access
PDF file
RYRuowen Yuan
Ruowen Yuan
JCJianshu Chen
Jianshu Chen
SZShangyun Zhang
Shangyun Zhang
XZXiaowei Zhang
Xiaowei Zhang
JYJing Yu
Jing Yu
Background and Objectives: The physiological phenomenon peculiar to women, namely menopause, makes the occurrence of left ventricular hypertrophy (LVH) in postmenopausal hypertensive women more characteristic. Less is known about the risk of developing LVH in Chinese postmenopausal hypertensive women. Thus, the present study was intended to design a nomogram for predicting the risk of developing LVH in Chinese postmenopausal hypertensive women. Materials and Methods: Postmenopausal hypertensive women aged between 49 and 68 years were divided into either the training set (n = 550) or the validation set (n = 284) in a 2:1 ratio. Patients in the validation set were followed up for one year. A stepwise multivariable logistic regression model was used to assess the predictors of LVH in postmenopausal women with hypertension. The best-fit nomogram was executed using R software. The calibration and decision curve were employed to verify the predictive accuracy of the nomogram. The results were evaluated in the validation set. Results: Menopause age (OR = 0.929, 95% CI 0.866–0.998, p = 0.044), BMI (OR = 1.067, 95% CI 1.019–1.116, p = 0.005), morning systolic blood pressure (SBP: OR = 1.050, 95% CI 1.032–1.069, p = 0.000), morning diastolic BP (DBP OR = 1.055, 95% CI 1.028–1.083, p = 0.003), angiotensin II receptor blocker (ARB) utilization rate (OR = 0.219, 95% CI 0.131–0.365, p = 0.000), LDL-C (OR = 1.460, 95% CI 1.090–1.954, p = 0.011) and cardio-ankle vascular index (CAVI) (OR = 1.415, 95% CI 1.139–1.757, p = 0.028) were associated with LVH in postmenopausal hypertension patients. The nomogram model was then developed using these variables. The internal validation trial showed that the nomogram model described herein had good performance in discriminating a C-index of 0.881 (95% CI: 0.837–0.924) and high quality of calibration plots. External validation of LVH-predictive nomogram results showed that the area under the ROC curve was 0.903 (95%CI 0.900–0.907). Conclusions: Our results indicate that the risk prediction nomogram model based on menopausal age, BMI, morning SBP, morning DBP, ARB utilization rate, LDL-C and CAVI has good accuracy and may provide useful references for the medical staff in the intuitive and individualized risk assessment in clinical practice.

12 November 2026 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
RFRu Feng
Ru Feng
LTLiyuan Tao
Liyuan Tao
XZXiaowei Zhang
Xiaowei Zhang
RYRuowen Yuan
Ruowen Yuan
Exercise intolerance is a primary clinical manifestation of heart failure (HF) that significantly reduces patients’ quality of life and independently predicts adverse prognosis. Despite reducing mortality and hospitalization, guideline-directed medical therapy has limited effects on exercise capacity. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have consistently reduced HF hospitalization and improved patient-reported symptoms and health status, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ), whereas their effects on objective exercise capacity, such as 6-minute walk distance (6MWD) and peak oxygen consumption (peak VO 2 ), have been less consistent across trials, with pooled effects below commonly cited minimal clinically important difference thresholds. This review compares the evidence maturity of the hemodynamic and peripheral skeletal muscle pathways through which SGLT2i may enhance exercise tolerance. Regarding hemodynamics, the reduction in exercise-induced pulmonary capillary wedge pressure (PCWP) and may improve right ventricular–pulmonary artery (RV-PA) coupling provide a plausible mechanism, although direct evidence is mainly from HFpEF and mediation has not been demonstrated across the broader HF population. Regarding skeletal muscle, animal and human biopsy studies suggest potential modulation of AMPK signaling and reduced myofiber atrophy, but the independent contribution remains unvalidated. These differences in evidence maturity highlight the need to distinguish mechanistic findings, patient-reported health status, and objective functional outcomes when evaluating SGLT2i.

27 June 2024 in Journal Of Hypertension
Verified
Journal Article
Closed access
RYRuowen Yuan
Ruowen Yuan